Online Supplement

Original Research
Pharmacodynamic Equivalence and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate With a Next-Generation Propellant Versus Hydrofluoroalkane-134a Propellant: A Randomized Phase 3 Study in Chronic Obstructive Pulmonary Disease

Matthew Camiolo, MD, PhD[1*] Hitesh Pandya, MBChB, MD[2] Mandeep Jassal, MD[3] Artur Bednarczyk, MD[4] Yubo Tan, MSc[5] Margareta Puu, PhL[6] David Petullo, MSc[7] Patrik Bondarov, MSc[8] Artur Mark-Pawlowicz, MD[4] Jie Mei, MD, PhD[9] Lars Pettersson, MSc[9] Mehul Patel, MBBS, FRCP PhD[2] MeiLan K. Han, MD, MS[10]

[1]Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States

[2]Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

[3]Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States

[4]Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland

[5]Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Mississauga, Canada

[6]Late R&I Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

[7]Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States


[8]Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

[9]Global Patient Safety BioPharmaceuticals, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden

[10]Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan, United States

**affiliation at the time of the study*

Figure S1. Participant Disposition (Safety Analysis Set)



Participants who completed treatment were defined as having Day 29 spirometry assessment completed for treatment. One patient completed the first treatment (placebo HFA-134a) but did not initiate treatments BGF HFA-134a or BGF HFO-1234ze and was not counted in either completion or discontinuation of BGF HFA-134a or BGF HFO-1234ze.

BGF=budesonide, glycopyrrolate, formoterol fumarate; HFA-134a=hydrofluoroalkane-134a; HFO-1234ze=hydrofluoroolefin-1234ze